MA28804B1 - Formulations d'acide suberoylanilide hydroxamique et leurs procedes de production - Google Patents

Formulations d'acide suberoylanilide hydroxamique et leurs procedes de production

Info

Publication number
MA28804B1
MA28804B1 MA29685A MA29685A MA28804B1 MA 28804 B1 MA28804 B1 MA 28804B1 MA 29685 A MA29685 A MA 29685A MA 29685 A MA29685 A MA 29685A MA 28804 B1 MA28804 B1 MA 28804B1
Authority
MA
Morocco
Prior art keywords
producing
methods
same
acid formulations
hydroxamic
Prior art date
Application number
MA29685A
Other languages
English (en)
French (fr)
Inventor
Jeannie Chow Wong
Aaron S Cote
Erik A Dienemann
Kimberly Gallagher
Craig Ikeda
Justin Moser
Pavol Rajniak
Robert A Reed
Cindy Starbuck
Hsien-Hsin Tung
Qingxi Wang
Benjamin Max Cohen
Vincent R Capodanno
Brian Sell
Thomas A Miller
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28804(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA28804B1 publication Critical patent/MA28804B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA29685A 2005-05-20 2007-02-16 Formulations d'acide suberoylanilide hydroxamique et leurs procedes de production MA28804B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US69312805P 2005-06-23 2005-06-23

Publications (1)

Publication Number Publication Date
MA28804B1 true MA28804B1 (fr) 2007-08-01

Family

ID=37452585

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29685A MA28804B1 (fr) 2005-05-20 2007-02-16 Formulations d'acide suberoylanilide hydroxamique et leurs procedes de production

Country Status (20)

Country Link
US (4) US8093295B2 (enExample)
EP (2) EP1853245A2 (enExample)
JP (2) JP5264174B2 (enExample)
KR (2) KR100884500B1 (enExample)
AR (1) AR055953A1 (enExample)
AU (3) AU2006249440C1 (enExample)
BR (1) BRPI0605893A (enExample)
CA (1) CA2580367C (enExample)
CR (1) CR8912A (enExample)
DO (1) DOP2006000113A (enExample)
EC (1) ECSP077263A (enExample)
IL (1) IL181070A0 (enExample)
MA (1) MA28804B1 (enExample)
MX (1) MX2007002047A (enExample)
MY (1) MY144613A (enExample)
NI (1) NI200700031A (enExample)
NZ (2) NZ594669A (enExample)
PE (1) PE20061390A1 (enExample)
TW (2) TWI415603B (enExample)
WO (2) WO2006127321A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme 1,8-辛二醯基苯胺羥胺酸(suberoylanilide hydroxamic acid)之調配物及其製配方法
AU2009305214B2 (en) 2008-10-15 2015-06-25 Generics [Uk] Limited Process for the preparation of vorinostat
US20110269838A1 (en) * 2008-11-26 2011-11-03 Vinayak Gore Novel processes and pure polymorphs
AU2009321384A1 (en) 2008-11-26 2011-06-23 Generics [Uk] Limited Polymorphs
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
US11060092B2 (en) 2016-07-13 2021-07-13 Technion Research & Development Foundation Limited Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
AU2020326612B2 (en) 2019-08-02 2025-10-23 Onehealthcompany, Inc. Treatment of canine cancers

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
JP2002527449A (ja) 1998-10-13 2002-08-27 藤沢薬品工業株式会社 環状テトラペプチド化合物およびその用途
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
US6511990B1 (en) * 1999-09-08 2003-01-28 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
AU2002318364A1 (en) * 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
JP4638148B2 (ja) * 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
EP2322160A1 (en) 2002-03-04 2011-05-18 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
JP2006508986A (ja) * 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
WO2004089293A2 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
PT1663194E (pt) * 2003-08-26 2010-07-06 Merck Hdac Res Llc Utilizaã†o de saha para o tratamento de mesotelioma
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme 1,8-辛二醯基苯胺羥胺酸(suberoylanilide hydroxamic acid)之調配物及其製配方法
JP2009504774A (ja) 2005-08-18 2009-02-05 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにsaha及びターグレチンの併用方法
US20090105329A1 (en) 2005-11-04 2009-04-23 Judy Chiao Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies
US20070197473A1 (en) * 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer
CA2622136A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer

Also Published As

Publication number Publication date
MX2007002047A (es) 2007-04-12
IL181070A0 (en) 2007-07-04
WO2006127319A2 (en) 2006-11-30
AU2009201652B2 (en) 2011-10-06
KR100993135B1 (ko) 2010-11-10
AU2006249440A1 (en) 2006-11-30
TWI365068B (en) 2012-06-01
JP2008519081A (ja) 2008-06-05
MY144613A (en) 2011-10-04
TW200727892A (en) 2007-08-01
EP2292221A2 (en) 2011-03-09
AU2009201650B2 (en) 2011-09-15
JP5264174B2 (ja) 2013-08-14
TWI415603B (zh) 2013-11-21
US20080132575A1 (en) 2008-06-05
NZ553204A (en) 2011-09-30
BRPI0605893A (pt) 2007-12-18
CA2580367C (en) 2012-08-21
PE20061390A1 (es) 2007-01-15
US20100113829A1 (en) 2010-05-06
EP1853245A2 (en) 2007-11-14
US20100119596A1 (en) 2010-05-13
WO2006127321A2 (en) 2006-11-30
NI200700031A (es) 2008-03-03
US8288440B2 (en) 2012-10-16
AU2006249440C1 (en) 2009-08-13
US20100112046A1 (en) 2010-05-06
JP5308486B2 (ja) 2013-10-09
AR055953A1 (es) 2007-09-12
JP2011251985A (ja) 2011-12-15
TW201034660A (en) 2010-10-01
KR20080113135A (ko) 2008-12-26
NZ594669A (en) 2013-02-22
AU2009201650A1 (en) 2009-05-21
EP2292221A3 (en) 2011-08-10
KR100884500B1 (ko) 2009-02-20
AU2009201652A1 (en) 2009-05-21
US8450372B2 (en) 2013-05-28
AU2010201359A1 (en) 2010-04-29
AU2006249440B2 (en) 2009-03-12
ECSP077263A (enExample) 2007-04-26
CR8912A (es) 2008-02-21
KR20070062505A (ko) 2007-06-15
WO2006127321A3 (en) 2007-03-22
US8093295B2 (en) 2012-01-10
CA2580367A1 (en) 2006-11-30
DOP2006000113A (es) 2006-10-31
WO2006127319A3 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
MA28804B1 (fr) Formulations d'acide suberoylanilide hydroxamique et leurs procedes de production
EP2097111A4 (en) HETERODIMERS OF GLUTAMIC ACID
FR2920966B1 (fr) Procede capillaire comprenant l'application d'une polyamine et d'un acide gras
EP2207896A4 (en) nucleic acid amplification
EP1883389A4 (en) COMPOSITIONS WITH LOW RICH POTENTIAL AND METHOD FOR THE PRODUCTION THEREOF
FR2925068B1 (fr) Procedes de production d'acide succinique
EP1916234A4 (en) Cyclopropanecarboxylate CONNECTION
EP1937268A4 (en) INDENOISOCHINOLINONE ANALOGUES AND METHOD OF USE THEREOF
EP2066350A4 (en) STABILIZED ANTIBODY FORMULATIONS AND THEIR USES
MA30684B1 (fr) Anticorps anti-mn et leurs procedes d'utilisation.
LU91534I2 (fr) "Acide nicotinique/laropiprant"
EP1907590A4 (en) MATERIALS AND METHOD FOR THE PRODUCTION OF COMPLETELY 2'-MODIFIED NUCLEIC ACID TRANSCRIPTS
EP1933639A4 (en) METHOD FOR PRODUCING SNACK FOODS AND PRODUCTS MANUFACTURED THEREFOR
EP2096912A4 (en) FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENOIC ACID DERIVATIVES
EP2017263A4 (en) Heteroarylamide derivative of a lower carboxylic acid
EP1931689A4 (en) ORGANIC IRON COMPOUNDS IN MEDICINAL QUALITY, USES THEREOF AND METHOD FOR THE MANUFACTURE THEREOF
EP2112219A4 (en) NOVEL MILKY ACID BACTERIA
EP1928995A4 (en) FORMULATIONS OF LIVABLE MICROORGANISMS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2104422A4 (en) EAST FOREST TREATMENT INHIBITION IN CHEMICAL FORMULATIONS
EP1767504A4 (en) PHOSPHORSÄUREESTERPOLYMER
EP1990416A4 (en) PROCESS FOR THE PREPARATION OF L-AMINO ACID
EP1979269A4 (en) CHLORINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
EP1976485A4 (en) LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF
EP1695956A4 (en) CYCLIC CARBONIC ACID CONNECTION AND ITS APPLICATION
EP1726638A4 (en) NEW MILKY ACID BACTERIUM